CN106266037B - 一种液体凝胶及其制备方法 - Google Patents
一种液体凝胶及其制备方法 Download PDFInfo
- Publication number
- CN106266037B CN106266037B CN201610694663.7A CN201610694663A CN106266037B CN 106266037 B CN106266037 B CN 106266037B CN 201610694663 A CN201610694663 A CN 201610694663A CN 106266037 B CN106266037 B CN 106266037B
- Authority
- CN
- China
- Prior art keywords
- parts
- gel
- chitosan
- hyaluronic acid
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000001879 gelation Methods 0.000 title description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 16
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960005040 miconazole nitrate Drugs 0.000 claims abstract description 15
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 9
- 229960001631 carbomer Drugs 0.000 claims abstract description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 241001092040 Crataegus Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种液体凝胶及其制备方法，其特征在于：该凝胶的成分包括：壳聚糖0.5‑2.5重量份，羟丙甲纤维素0.5‑5重量份，聚乙二醇6000 0.5‑6重量份，醋酸氯已定0.1‑0.3重量份、卡波姆0.1‑3重量份、丙二醇0.1‑2重量份、山楂核0.1‑3重量份，透明质酸类物质0.2～2重量份，硝酸咪康唑0.01‑0.5重量份，纯化水50‑70重量份，pH值5—7.5。具有副作用小、疗效好，且不易导致生殖道菌群失衡、能有效缓解或者治愈病情的优点。
Description
技术领域
本发明涉及凝胶材料技术领域，具体涉及一种液体凝胶及其制备方法。
背景技术
随着生活观念的改变以及周围环境的恶化，生殖道感染在女性中越来越成为常见病和多发病。其主要是发生在女性生殖***的一类感染性疾病，主要通过性途径进行传播，其中以***炎最为常见。而如果采用口服药物治疗，一来副作用大，二来不能直接作用于患处，疗效不显著；目前，也有使用凝胶材料直接进行作用于患处作用，这样起效快、疗效显著，但是还是存在一定的不足：比如化学试剂成分含量大，仍然有较大的副作用，此外，还容易造成***菌群失衡，不能有效缓解或者治愈病情。
发明内容
本发明针对现有技术的上述不足，提供一种副作用小、疗效好，且不易导致生殖道菌群失衡、能有效缓解或者治愈病情的液体凝胶。
为了解决上述技术问题，本发明采用的技术方案为：一种液体凝胶，该凝胶的成分包括：壳聚糖0.5-2.5重量份，羟丙甲纤维素0.5-5重量份，聚乙二醇6000 0.5-6重量份，醋酸氯已定0.1-0.3重量份、卡波姆0.1-3重量份、丙二醇0.1-2重量份、山楂核0.1-3重量份，透明质酸类物质0.2～2重量份，硝酸咪康唑0.01-0.5重量份，纯化水50-70重量份，pH值5—7.5。
作为进一步优选，本发明上述的液体凝胶，该凝胶的成分包括：壳聚糖1-2重量份，羟丙甲纤维素1-4重量份，聚乙二醇6000 1-3重量份，醋酸氯已定0.15-0.25重量份、卡波姆0.15-2重量份、丙二醇0.5-1重量份、山楂核0.5-2重量份，透明质酸类物质0.5～1.5重量份，硝酸咪康唑0.02-0.3重量份，纯化水55-65重量份，pH值5—7.5。
本发明上述的透明质酸类物质为透明质酸钠。
本发明还提供一种上述液体凝胶的制备方法，制备步骤包括：
(1)按照配方比例先将壳聚糖溶解于纯化水中，充分溶胀后待用；
(2)按照配方比例将透明质酸类物质溶解于纯化水中，充分溶胀后待用；
(3)将配方比例中剩余的其它组分混合均匀；
(4)将步骤(1)-(3)所得的溶液加入同一个容器中，充分搅拌混匀，调节pH值5—7.5得到凝胶产品。
本发明的优点和有益效果：
1.本发明首次将壳聚糖和硝酸咪康唑同时使用，壳聚糖具有广谱抗菌、无耐药性、杀菌能力强和对***无刺激性等特点，副作用小，而结合硝酸咪康唑同时使用则充分提高了药效，因为硝酸咪康唑为广谱抗真菌药，对多种真菌，尤其是念珠菌有抗菌作用，对某些革兰阳性杆菌和球菌也有抗菌作用。其作用机制是抑制真菌细胞膜的合成，以及影响其代谢过程。
2.本发明的产品中使用了山楂核和卡波姆，能够充分实现生殖道内的微生物生态平衡和pH平稳，提高***对各种致病条件的抵抗力，有效预防外界细菌或病原生物的人侵，对细菌的抵抗进一步上升；卡波姆可将失活的HPV吸附、包裹排出体外，并加速糜烂组织的快速修复和再生，促进愈合，山楂核等还能改善***异味、改善***微环境、减轻***炎性反应、减少***分泌物量，有效改善***清洁度、降低***pH值，有效治疗***、***等妇科疾病。
具体实施方式
下面结合实施方式对本发明作进一步详细地说明，但不仅限于以下实施例。
实施例1
该凝胶的成分包括：壳聚糖2重量份，羟丙甲纤维素2重量份，聚乙二醇6000 2重量份，醋酸氯已定0.2重量份、卡波姆0.15重量份、丙二醇0.15重量份、山楂核2重量份，透明质酸类物质1.5重量份，硝酸咪康唑0.02重量份，纯化水55重量份，pH值6.5。
具体步骤包括：
(1)按照配方比例先将壳聚糖溶解于纯化水中，充分溶胀后待用；
(2)按照配方比例将透明质酸类物质溶解于纯化水中，充分溶胀后待用；
(3)将配方比例中剩余的其它组分混合均匀；
(4)将步骤(1)-(3)所得的溶液加入同一个容器中，充分搅拌混匀，调节pH值得到凝胶产品。
步骤(1)和(2)的用水量之和为凝胶配方中总纯化水的用水量。
实施例2
该凝胶的成分包括：壳聚糖1.5重量份，羟丙甲纤维素1重量份，聚乙二醇6000 1重量份，醋酸氯已定0.2重量份、卡波姆0.3重量份、丙二醇0.8重量份、山楂核1重量份，透明质酸类物质1重量份，硝酸咪康唑0.025重量份，纯化水60重量份，pH值77。
方法同实施例1。
实施例3
该凝胶的成分包括：壳聚糖2重量份，羟丙甲纤维素3重量份，聚乙二醇6000 2.5重量份，醋酸氯已定0.20重量份、卡波姆0.20重量份、丙二醇0.6重量份、山楂核0.6重量份，透明质酸类物质1.0重量份，硝酸咪康唑0.05重量份，纯化水55重量份，pH值6。
方法同实施例1。
对比例
该凝胶的成分中的硝酸咪康唑去除，其它成分同实施例3不变化，方法同实施例1。
本发明实施例制备的样品，使用效果：将志愿者平均分成3组，每组80人。第一组(试验组)志愿者每天晚上用温开水清洗***后，取实施例1制备的凝胶剂3g涂覆于***周围和***内部；第二组(对照组)取市售***炎抗菌凝胶作对照，每次用量3g；每组连续使用给药两周后进行第一次复查，五周后第二次复查；第三组(对比例组)取对比例***炎抗菌凝胶作对照，每次用量3g；每组连续使用给药两周后进行第一次复查，五周后第二次复查结果见表1。
表1两组患者临床疗效对比
| 组别 | N | 治愈 | 显效 | 无效 | 总有效率 |
| 观察组 | 80 | 68 | 10 | 2 | 97.5％ |
| 对照组 | 80 | 50 | 8 | 22 | 72.5％ |
| 对比例组 | 80 | 65 | 8 | 15 | 91.25％ |
从上表可知，本发明制备的凝胶具有治愈率高、疗效好的优点；而且壳聚糖和硝酸咪康唑同时使用和使用一种效果差异显著，证明二者同时使用治愈率更高。
Claims (2)
1.一种液体凝胶，其特征在于：该凝胶的成分包括：壳聚糖0.5-2.5重量份，羟丙甲纤维素0.5-5重量份，聚乙二醇6000 0.5-6重量份，醋酸氯已定0.1-0.3重量份、卡波姆0.1-3重量份、丙二醇0.1-2重量份、山楂核 0.1-3重量份，透明质酸类物质 0.2 ～ 2 重量份，硝酸咪康唑0.01-0.5重量份，纯化水50-70重量份，pH值5—7.5;
制备步骤包括：
（1）将壳聚糖聚合物溶解于的水中，充分溶胀后待用；
（2）将透明质酸类物质加入水中，充分溶胀后待用；
（3）将其它组分混合均匀；
（4）将步骤（1）-（3）所得的溶液加入同一个容器中，充分搅拌混匀，调节pH值5—7.5得到凝胶产品。
2.根据权利要求1所述的液体凝胶，其特征在于：该凝胶的成分包括：壳聚糖1-2重量份，羟丙甲纤维素1-4重量份，聚乙二醇6000 1-3重量份，醋酸氯已定0.15-0.25重量份、卡波姆0.15-2重量份、丙二醇0.5-1重量份、山楂核 0.5-2重量份，透明质酸类物质0.5 ～1.5 重量份，硝酸咪康唑0.02-0.3重量份，纯化水55-65重量份，pH值5—7.5。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610694663.7A CN106266037B (zh) | 2016-08-19 | 2016-08-19 | 一种液体凝胶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610694663.7A CN106266037B (zh) | 2016-08-19 | 2016-08-19 | 一种液体凝胶及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106266037A CN106266037A (zh) | 2017-01-04 |
| CN106266037B true CN106266037B (zh) | 2020-09-29 |
Family
ID=57661720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610694663.7A Expired - Fee Related CN106266037B (zh) | 2016-08-19 | 2016-08-19 | 一种液体凝胶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266037B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080733A (zh) * | 2017-04-17 | 2017-08-22 | 滨州医学院附属医院 | 一种硝酸咪康唑壳聚糖***缓释凝胶及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422448A (zh) * | 2008-12-10 | 2009-05-06 | 李海涛 | 一种硝酸咪康唑膜剂及其制备方法和在制药中的应用 |
| CN102626524A (zh) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | 壳聚糖妇科抗菌凝胶及其制备方法 |
| CN103316033A (zh) * | 2013-07-03 | 2013-09-25 | 康晓飞 | 一种凝胶剂及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
-
2016
- 2016-08-19 CN CN201610694663.7A patent/CN106266037B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422448A (zh) * | 2008-12-10 | 2009-05-06 | 李海涛 | 一种硝酸咪康唑膜剂及其制备方法和在制药中的应用 |
| CN102626524A (zh) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | 壳聚糖妇科抗菌凝胶及其制备方法 |
| CN103316033A (zh) * | 2013-07-03 | 2013-09-25 | 康晓飞 | 一种凝胶剂及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106266037A (zh) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110464811A (zh) | 一种妇科用泡沫抑菌液及其制备方法 | |
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| CN104224923A (zh) | 治疗妇科***疾病的茶树精油抗菌凝胶 | |
| US20080161234A1 (en) | Composition Comprising Lactic Acid and Lactoferrin | |
| CN109771368A (zh) | 一种抑菌凝胶及其制备方法 | |
| CN111449973A (zh) | 一种修复女性***微生态平衡的泡沫剂及其制备方法 | |
| CN108853003A (zh) | 一种硝呋太尔-制霉素软胶囊型栓剂及其制备方法 | |
| CN113730433B (zh) | 一种治疗***炎症的妇科凝胶及其制备方法与应用 | |
| CN109010124B (zh) | 一种海洋精粹妇科抑菌凝胶及其制备方法 | |
| CN114652748A (zh) | 一种含有干细胞抑菌因子的医用妇科洗液的制备方法及其应用 | |
| CN106266037B (zh) | 一种液体凝胶及其制备方法 | |
| CN104069124B (zh) | 用于妇科感染的组合物及制剂 | |
| CN103191408A (zh) | 一种治疗***炎的药物组合物、凝胶剂及其用途 | |
| WO2021036294A1 (zh) | 一种***酸碱缓冲凝胶及制备方法 | |
| CN106214882A (zh) | 一种高强度抗菌液体凝胶及其制备方法 | |
| CN109985037A (zh) | 一种妇科凝胶 | |
| CN110124017A (zh) | 一种抑菌凝胶 | |
| CN115837046A (zh) | 一种奥硝唑***栓剂及其制备方法 | |
| CN113662998A (zh) | 一种用于治疗***炎和妇科炎症的药物组合物及制备方法 | |
| CN101933895A (zh) | 硝酸芬替康唑的***栓剂组合物 | |
| CN106177274B (zh) | 一种避孕凝胶组合物及其制备方法 | |
| KR20120005260A (ko) | 해당근 발효 추출물을 유효성분으로 포함하는 여성 청결용 화장료 조성물 | |
| CN103768089A (zh) | 一种壳聚糖妇科抗菌洗液及其制备方法 | |
| CN110193004A (zh) | 含生物抑菌肽的女性抑菌凝胶及其制备方法 | |
| CN102526121A (zh) | 一种创面修复组合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200929 |